MK-677 Ibutamoren Capsules

What is MK-677 (Ibutamoren)?

MK-677 Ibutamoren Capsules contain a synthetic non-peptide small molecule. It is classified as a selective, orally active agonist of the growth hormone secretagogue receptor subtype 1a (GHSR-1a). Researchers also refer to it by the developmental codes MK-0677 and L-163,191. Laboratories seeking MK-677 ibutamoren capsules for sale from a verified research supplier will find this compound classified strictly as a research-grade small-molecule tool.

MK-677 is not a peptide. Its sulfonamide backbone allows oral bioavailability in preclinical settings. It is a structural characteristic that distinguishes it from peptide-based secretagogues that are degraded in the gastrointestinal tract. As an oral growth hormone peptide secretagogue surrogate, MK-677 is frequently selected for experimental designs that require non-injectable activation of GHSR-1a. Researchers looking to buy MK-677 capsules in the USA should note that BehemothLabz supplies this compound exclusively for laboratory and research purposes, with independent third-party purity verification on every batch.

ATTENTION: This product is strictly for LABORATORY AND RESEARCH PURPOSES ONLY. Not for human or veterinary use.

Mechanism of Action of MK-677 Ibutamoren Capsules

How Does MK-677 Interact with GHSR-1a?

MK-677 is a selective GHSR-1a agonist. It binds to the ghrelin receptor in the hypothalamus and pituitary gland, initiating a downstream signaling cascade that drives somatotropic axis activity in experimental models. As a ghrelin mimetic compound, MK-677 replicates the receptor-level binding profile of endogenous ghrelin without sharing its peptide structure, making it a structurally distinct tool for dissecting GHSR-1a-mediated signaling in preclinical systems.

High-resolution cryo-EM structural studies have characterized the molecular basis of MK-677’s binding to GHSR-1a. This reveals a defined agonist-binding pocket, a salt bridge, and an aromatic cluster as key structural motifs in receptor activation. This interaction stabilizes the GHSR-Gᵢ signaling complex and initiates intracellular signal transduction. [Liu et al., 2021] 

Key mechanistic observations from laboratory studies:

Gαq/11 signaling activation: MK-677 binding to GHSR-1a activates Gαq/11-coupled intracellular pathways. This leads to upregulation of somatotropic-axis-associated peptide signaling in experimental models.

GH pulse stimulation: In preclinical models, GHSR-1a activation by MK-677 is associated with pulsatile GH release from the anterior pituitary. The pulsatile pattern mirrors that of endogenous GH secretion. In this context, MK-677 is studied as an MK-677 growth hormone secretagogue probe capable of recapitulating physiological GH pulse architecture in rodent experimental systems.

IGF-1 pathway engagement: Rodent model studies have examined somatostatin mRNA expression, GHSR mRNA levels, and somatotropic axis feedback under MK-677 administration, providing a mechanistic framework for investigating GH-IGF-1 axis dynamics. MK-677 is examined in these settings as an IGF-1 stimulator capsule reference compound for downstream pathway analysis in metabolic and growth factor research models.

Somatostatin counterregulation: In prolonged rodent administration studies, increases in hypothalamic SST mRNA expression were observed alongside decreased SSTR-2 expression in the pituitary. This indicates active neuroendocrine counterregulatory responses in the experimental model. [Lee et al., 2018] 

Androgen receptor independence: MK-677 is thought to exhibit no significant affinity for androgen receptor pathways. This distinguishes it from SARMs and supports its use as a selective GHSR-1a probe in research designs requiring separation of androgenic and somatotropic signaling.

Properties of MK-677 Ibutamoren Capsules

Property	Detail
Molecular Formula	C₂₇H₃₆N₄O₅S
IUPAC Name	2-amino-2-methyl-N-[1-(1-methylsulfonylspiro[2H-indole-3,4′-piperidine]-1′-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide
Synonyms	Ibutamoren, MK-0677, L-163,191, CHEMBL13817, Oratrope
Molecular Weight	528.67 g/mol
CAS Number	159634-47-6
PubChem CID	9939050
Purity	≥99% (HPLC verified, per batch COA)
Physical Form	White lyophilized powder
Storage	−20°C, protected from light and moisture
Form	Free base (not mesylate salt)
Classification	Research Use Only (RUO)

Research Applications of MK-677 Ibutamoren Capsules

MK-677 Ibutamoren Capsules are studied across several experimental research domains. Researchers sourcing ibutamoren research-grade capsules for controlled preclinical studies will find the compound applicable across the five domains outlined below.

1. GHSR-1a Receptor Signaling Studies

MK-677’s high selectivity and oral bioavailability make it a useful molecular tool for investigating GHSR-1a receptor binding dynamics, Gαq/11-coupled signal transduction, and downstream somatotropic pathway activation. Cryo-EM structural data reveal the molecular framework for GHSR signaling and provide a basis for developing new GHSR agonist research tools. Although MK-677 is supplied here in free base form rather than as ibutamoren mesylate capsules, both forms engage the same GHSR-1a binding site; researchers should note this distinction when comparing pharmacokinetic datasets across experimental systems.

2. Somatotropic Axis Research

In preclinical models, MK-677 has been studied for its ability to stimulate pulsatile GH release from the anterior pituitary via GHSR-1a activation. This makes it a relevant research tool for investigating GH-IGF-1 axis dynamics, including neuroendocrine feedback mechanisms involving somatostatin and GHRH in rodent and in vitro models. Some investigative frameworks have examined this compound in the context of MK-677 bone density study designs, where GH-IGF-1 axis activation in preclinical models provides a mechanistic basis for studying downstream effects on bone mineral metabolism markers. Findings in this area remain preclinical, and data are not consistent across all model systems.

3. Neuroendocrine Feedback Mechanism Analysis

Laboratory studies in rats have examined SST mRNA upregulation and SSTR-2 receptor expression changes following MK-677 administration, providing a model for studying compensatory neuroendocrine feedback in the somatotropic axis. Separately, preclinical sleep architecture studies have incorporated MK-677 as a tool compound, given GHSR-1a’s role in modulating slow-wave sleep patterns in rodent models. This body of preclinical work is referenced in ibutamoren sleep quality research contexts, though all such findings derive from animal model settings and have not been validated in controlled human studies.

4. Metabolic Substrate and Signaling Pathway Research

MK-677 has been examined in preclinical metabolic models for its apparent influence on glucose-related and lipid-associated molecular pathways downstream of IGF-1 pathway activation. Findings in this area remain limited, and data across experimental systems are not fully consistent. Preclinical investigations examining muscle tissue anabolism signaling markers have included MK-677 as a reference compound in MK-677 muscle growth research designs, where IGF-1-mediated anabolic pathway activity is the primary investigative endpoint. These are in vitro and rodent model findings only. Researchers should also note that MK-677 is occasionally described in informal literature as an MK677 HGH booster, a designation that reflects its somatotropic axis activity in preclinical models but does not constitute a characterization applicable to the research-grade formulation supplied here, which carries no therapeutic classification of any kind.

Risk and Handling Precautions

Risk Tier: MODERATE

Handling Precautions: MK-677 capsules should be handled by trained laboratory personnel only. Use appropriate personal protective equipment (PPE) at all times, including gloves and eye protection. Avoid direct skin contact and inhalation during laboratory handling.

Exposure Risks: No human safety data has been established for the research-grade formulation supplied here. No human safety data has been established for the research-grade formulation supplied here. MK-677 underwent Phase 2 clinical investigation before Merck discontinued its regulatory development programme. No toxicological profile exists for this research-grade preparation, and findings from those clinical studies do not apply here.

Storage: Store at −20°C in a dry, dark environment protected from light, heat, and moisture. Check the batch Certificate of Analysis for lot-specific guidance. Do not use if the seal has been compromised.

Regulatory Status: MK-677 (Ibutamoren) is classified as a prohibited substance under the World Anti-Doping Agency (WADA) Prohibited List (category S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics). This product is supplied strictly for controlled laboratory research and must not be used in any context involving athletic competition or human subjects.

Toxicity and Data Limitations: No chronic toxicity data exist for this research-grade preparation.MK-677 underwent Phase 2 clinical investigation across multiple indications — including studies in healthy elderly subjects, GH-deficient adults, obese males, and hip fracture patients — before Merck discontinued its regulatory development programme. Published Phase 2 data from these studies exist in peer-reviewed literature. However, those findings do not apply to the research-grade formulation supplied here and are cited for pharmacological context only. Long-term exposure effects and systemic toxicity thresholds have not been characterized for this research preparation.

Why Choose BehemothLabz to Buy MK-677 Ibutamoren Capsules?

Behemoth Labz offers MK-677 (Ibutamoren) Capsules for laboratory research. Every batch goes through independent third-party testing for purity, identity, and contaminant screening. Testing is conducted using HPLC (High Performance Liquid Chromatography) and FTIR spectroscopy. Researchers looking for the best MK-677 capsules online for controlled laboratory applications will find BehemothLabz’s supply standards meet independent verification requirements, with every lot confirmed at ≥99% purity before release.

Each product batch carries a unique batch number linked to a publicly accessible Certificate of Analysis (COA). BehemothLabz does not self-certify. External labs verify every lot. This confirms purity at ≥99% and supports consistent research-grade standards per batch.

BehemothLabz Disclaimer

ATTENTION: All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

Please make sure you go through the Terms and Conditions and familiarize yourself with them, as it is important. Kindly research the scientific uses of this product before making any purchases. Make note that the packaging and labels of the product may differ from those shown on the website.

By purchasing the product, you agree to our Terms and Conditions. You can contact our customer service team at support@behemothlabz.com if you are not fully satisfied with the product.

MK-677 Ibutamoren Capsules Research FAQs

What purity standard does BehemothLabz provide for this product? Every batch is independently tested by third-party laboratories. MK-677 Ibutamoren Capsules are verified at ≥99% purity by HPLC analysis. A Certificate of Analysis confirming purity and molecular identity is available per lot.

Is MK-677 a SARM? No. MK-677 is not a SARM. SARMs are selective androgen receptor modulators. MK-677 acts on GHSR-1a (the ghrelin receptor). It is a growth hormone secretagogue, not an androgen receptor ligand.

Is MK-677 approved for human use? No. MK-677 Ibutamoren is not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. No regulatory body has cleared it for any health application. BehemothLabz sells it for laboratory research purposes only. Please review the Terms and Conditions before ordering.

What effects has MK-677 demonstrated on testosterone in preclinical models? Available preclinical data show no consistent change in testosterone levels following MK-677 administration in animal models. Some studies document mild variation in GH/IGF-1 levels with extended administration periods. Findings are not consistent across experimental systems.

References

Chapman, I. M., Bach, M. A., Van Cauter, E., Farmer, M., Krupa, D., Taylor, A. M., Schilling, L. M., Cole, K. Y., Skiles, E. H., Pezzoli, S. S., Hartman, M. L., Veldhuis, J. D., Gormley, G. J., & Thorner, M. O. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism, 81(12), 4249–4257. https://pubmed.ncbi.nlm.nih.gov/8954023/ [Cited for pharmacological context only. Documents human clinical Phase 2 research and does not apply to the research-grade formulation supplied here.]

Nass, R., Pezzoli, S. S., Oliveri, M. C., Patrie, J. T., Harrell, F. E., Clasey, J. L., Heymsfield, S. B., Bach, M. A., Vance, M. L., & Thorner, M. O. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine, 149(9), 601–611. https://pubmed.ncbi.nlm.nih.gov/18981485/ [Cited for pharmacological context only. Documents human clinical Phase 2 research and does not apply to the research-grade formulation supplied here.]